echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Injection bi-valaized reedding by Fosun 50 million revenue pocket sales growth has exceeded 800%

    Injection bi-valaized reedding by Fosun 50 million revenue pocket sales growth has exceeded 800%

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Figure 1: Sales of end-use injections in China's public medical institutions (units: 10,000 yuan) Source: Minet China Public Medical InstitutionS Terminal Competition Pattern than The Law Reflux as antithrombotic drugs, is a reversible action of specific clotting enzyme inhibitors.
    injection serotonin indicationisis is used as an anticoagulant for adult transdermal coronary artery intraenterosome (PTCA) and transdermal coronary artery interventional therapy (PCI), and for patients in PCI with heparin-induced platelet reduction (HIT) or heparin-induced platelet reduction and thrombosis syndrome (HITTS) risk.
    According to Minet data, in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminals, injection sales in recent years than the scale of sales of the rapid lying trend, the peak growth rate in 2015 reached 838.54 percent, the first time in that year sales exceeded 100 million yuan;
    the current market leader for Xinlitai, 2018 market share of 85.67% Figure 2: injection than the domestic approval situation of the bi-dea-ding source: Minnet net one-click search of the injection of double-into-the-drug industry than the reed is scheduled to be approved in January 2019, registered as 6 types of imitation.
    January 2020, Qilu Pharmaceutical's injection-by-comparison of 3 types of imitation listing application was approved, becoming the first approved enterprise of the product.
    Shuangcheng Pharmaceuticals, signed on December 13, 2019, refers to all product rights of the transferred product in the designated region (the region refers to the People's Republic of China, including Taiwan, Hong Kong Special Administrative Region and Macao Special Administrative Region), including, but not limited to, commercial rights (distribution, sales, marketing, doctor-patient education, etc.), free production rights, brand ingventancy, product redevelopment, etc.;
    Source: Company Announcement, Minnet Database Original Title: "Remarkable" annual sales of 400 million anti-thrombotic drugs by Fosun 50 million revenue bags, sales growth rate has exceeded 800%
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.